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Abstract: 
Since the introduction of erythropoiesis-stimulating agents (ESAs) into clinical practice in 1989, 
considerable effort has been put forth towards identifying the optimal treatment strategy for 
managing anemia of chronic kidney disease (CKD). After initial treatment of only the most 
severely anemic patients, treatment was subsequently expanded to include most patients on 
dialysis and many non-dialysis CKD patients. Many nephrology societies and regulatory agencies 
have sought to identify the most appropriate hemoglobin levels to which ESA therapy should be 
targeted. As increasing evidence became available about the impacts of ESAs on varying 
endpoints including morbidity, mortality, and quality of life, the guidelines put forth by such 
agencies evolved over time. We will review the literature impacting these determinations 
through the past three decades and comment on how this informs the application of this 
knowledge to the care of patients today. 
 
Clinical Summary: 
• Target hemoglobin levels as recommended in guidelines by various organizations have 
evolved over time. 
• Initial trends of increasing target hemoglobin levels were halted and partially reversed by 
trials revealing increased morbidity and mortality at higher targets. 
• Due to limitations in the available data, it remains difficult to pinpoint a specific target range 
and within some boundaries clinician judgment about the appropriate target for a given 
patient remains paramount. 
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Introduction 
Anemia is a frequent complication in patients with advanced CKD and affects a substantial 
majority of patients with ESKD. (1) Anemia is associated with decreased exercise tolerance, 
fatigue, and generally poorer quality of life. (2) The pathogenesis of anemia in CKD includes 
inadequate erythropoietin production. (3) Recombinant human erythropoietin (epoetin alfa) 
was first approved by the U.S. Food and Drug administration (FDA) in 1989 following a series of 
studies demonstrating safety, reduced need for blood transfusions, and improved quality of life 
(QoL) in patients on dialysis. (4-7) The approval of epoetin alfa was greeted with enthusiasm 
and saw its widespread application in management of patients with severe anemia.  Therapy 
with epoetin alfa and later other erythropoiesis stimulating agents (ESAs) gradually broadened 
to less severely anemic patients. Over time, identification of the optimal hemoglobin (Hb) level 
for patients with ESKD and CKD has been a subject of considerable source of controversy.  This 
review will explore the literature that informed guidelines and regulations over the three 
decades since epoetin alfa was first brought to market.   
 
Initial Approval of Epoetin 
Prior to the availability of recombinant human erythropoietin analogs, anemia was treated with 
frequent red blood cell transfusions. In the initial phase III study by Eschbach et al. of epoetin 
alfa, mean hematocrit (Hct) prior to treatment was 22.3%, corresponding to a Hb of 7.5 g/dL. 
(4) In the six months prior to study initiation, the 333 study patients received a total of 1030 
RBC transfusions, at an average rate of 0.52 transfusions per patient per month.  This initial 
study targeted a Hct of 35% +/- 3%. After 2 months of therapy, the average RBC transfusion 
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rate was <0.03 per patient per month and most often needed if blood was lost with surgery or 
dialysis. In early studies of QoL in patients treated with ESAs, improvements included energy 
and activity level, functional ability, sleep and eating behavior, disease symptoms, health status, 
satisfaction with health, sex life, well-being, psychological affect, life satisfaction, and 
happiness. (8) 
 
The FDA approved epoetin alfa in June 1989 with a target Hct on the prescribing information of 
30-33%. (9) In the label, it was advised that the maximum Hgb should be 36%, above which the 
medication should be held. Why the FDA chose this target range was a subject of dispute since 
higher Hct levels had been targeted in the pre-approval trials. (10) Reimbursement for EPO 
administration was withheld by the Health Care Finance Administration when Hct was above 
36%.  
 
In the ensuing years, studies were undertaken to understand the potential effects of higher 
Hct/Hb levels. In sum, various trials targeting higher Hb levels demonstrated: no increase in 
progression of CKD with a suggestion that treating to higher levels would delay progression of 
CKD;  safety in PD;  lack of benefit in regressing left ventricular hypertrophy (LVH); 
improvement in fatigue;  and reduction in transfusions. (11-16) 
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Dialysis Outcomes Quality Initiative (DOQI) 
The 1997 Dialysis Outcomes Quality Initiative (DOQI) recommendations for anemia 
management with erythropoietin analogs recommended a target Hct of 33-36. (16) The Anemia 
Work Group cited multiple lines of evidence for this higher target. For one, shorter survival in 
patients was observed with lower Hb 9.9 vs. 11.3. (17)  Next, lower Hb is associated with LVH 
and the LVH was associated with a 2.9-fold increase in mortality rates. (18) Epoetin treatment 
was shown to induce partial regression of LVH. (19) Studies of QoL indicated negligible benefits 
in increasing from Hb of 8 up to 9-10, whereas benefits were observed with increases from 8 to 
10 to 12 or higher. (20-22) Third, comparison of the achieved Hct of 35% in the phase III study 
and 30% in the phase IV study showed improved QoL at 35%. (4,23) In one cited study 
significantly improved health-related quality of life (HRQOL) scores among predialysis CKD 
patients across a variety of study instruments used by trained interviewers were observed in 
the treated group. (23) Fourth, exercise capacity improved in patients treated Hct >36% 
compared to those with Hct of approximately 30%. (25)  
 
A few studies indicated potential downsides to higher target Hb including increased thrombosis 
and reduced dialysis clearance of certain solutes. (26) Preliminary results of the Normal 
Hematocrit Cardiovascular Trial (NHCT) also created a note for concern. (15) However, these 
negative signals were generally thought to be of questionable importance given the bulk of 
studies supporting higher Hct/Hb targets. (15) Enthusiasm for higher and hypothetically more 
physiologically normal Hb led to a series of randomized controlled trials searching for more 
definitive support of such targets. 
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Trials Before 2006 
The first was the prospective, randomized, double-blind, open label NHCT by Besarab et al. (27) 
Published in 1998, the trial enrolled 1233 prevalent hemodialysis patients with CHF or ischemic 
heart disease. The principal objective was to compare time to event outcomes between 
patients treated with epoetin alfa to a ‘normal’ Hct of 42% +/- 3% vs. a lesser correction to 30% 
+/- 3%. The trial was discontinued at an interim analysis when the group treated to the Hct of 
experienced more (202 events; 33%) of the primary endpoint of combined nonfatal MI and 
death compared to patients at Hct of 30 (164 events; 27%). The risk ratio for the primary end-
point in the “normal-hematocrit” group was 1.3, with 95% CI 0.9-1.9, indicating a nonsignificant 
but nonetheless concerning trend towards increased events. Due to this safety signal and the 
low probability of confirming the principal hypothesis, the study was stopped prior to its 
completion. In addition, there were higher rates of access thrombosis in the higher Hct arm: 
243 patients (39%) vs. 176 patients (29%) in the low Hct arm (p=0.001). Benefits to higher 
hemoglobin were also observed. Overall mortality was less at higher Hct values. Physical 
function scores on quality of life assessments Medical Outcomes Study Short Form Health 
Survey (SF-36) were significantly improved in the higher Hct arm, although this has been 
disputed in a reanalysis of the data (28). Except for patients with known cardiac disease, the 
NHCT did not immediately lead to any change in guideline recommendations. However, it laid 
the groundwork for later studies that ultimately led to Hct/Hb lower targets. 
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Investigators from Canada and Europe conducted a double blind RCT in 596 incident 
hemodialysis patients comparing lower (9.5-11.5 g/dL) and higher (13.5-14.5) Hb targets. 
(14,15) This study’s principal hypothesis was that higher Hb would result in a lower incidence of 
LVH as assessed by left ventricular volume index. Achieved Hb levels were 13.3 and 10.9 in the 
higher and lower target groups, respectively. There was no significant difference in LVH 
between the two groups (P=0.87). Mortality was similar, with 13 and 20 deaths in the higher 
and lower target groups, respectively.  
 
Effects of normalization of Hb was examined in a Scandinavian trial of 416 pre-dialysis, 
hemodialysis and peritoneal dialysis patients. (29) This prospective, open-label, randomized 
trial compared subnormal hemoglobin (9-12 g/dL) to normal hemoglobin (13.5-15 g/dL in 
females and 14.5-16 g/dL in males). The study’s aim was to compare mortality, adverse events, 
and QoL in CKD patients. Enrollment began in 1995. Protocol changes were undertaken to 
exclude patients with significant cardiovascular comorbidity after preliminary results of the 
NHCT became available in 1996. This contributed to a high withdrawal rate and limited final 
conclusions. Overall mortality was very similar with 29 deaths (13.4%) in the normal Hb arm 
and 27 deaths (13.5%) in the subnormal Hb arm. Additional results from this and other large 
trials are presented in Table 1.  
 
The 2006 Kidney Disease Outcomes Quality Initiative (KDOQI) anemia guidelines initially 
recommended a target Hb of >11 g/dL, but not necessarily higher than 13 g/dL. (30)  These 
guidelines were motivated by reports indicating higher QoL and observational associations of 
 7 
decreased mortality at higher Hb levels. (10) Subsequent trial reports would lead to a revision 
of the KDOQI Hb target to 11-12 g/dL the following year. 
 
CHOIR, CREATE, TREAT and Subsequent Analyses 
The open-label Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) RCT 
published in November 2006 compared outcomes in 1432 nondialysis CKD (CKD 3-4; eGFR 15-
50) patients in terms of a composite primary endpoint of death, MI, and hospitalization for 
heart failure. (31) Singh et al. assigned 715 subjects to a target Hb of 13.5 g/dl and 717 subjects 
to 11.3 g/dL. There were 125 events in the high Hb group compared to 97 events in the low Hb 
group (hazard ratio [HR] 1.34; 95% CI: 1.03 to 1.74, P=0.03). Similar to the NHCT, this study was 
stopped at an interim analysis because of the safety issues and very low probability of showing 
a positive result with continuation. Hospitalization occurred more often with high Hb, 369 
(51.6%) vs. 334 (46.6%) of patients (P=0.03). Serious adverse events occurred more often with 
high Hb (P=0.02) and were most pronounced for congestive heart failure (P=0.02). The authors 
concluded the abstract, “The use of a target hemoglobin level of 13.5 g per deciliter (as 
compared with 11.3 g per deciliter) was associated with an increased risk and no incremental 
improvement in the quality of life.” 
 
Cardiovascular Risk Reduction by Early Anemia Treatment (CREATE) open-label RCT was 
published at the same time as CHOIR. Drüeke et al. randomized 603 European nondialysis CKD 
(eGFR 15-35) patients to Hb 13-15g/dL (group 1) vs. Hb 10.5-11.5 g/dL (group 2) utilizing 
epoetin beta. (32) The primary endpoint was time to first of eight cardiovascular events.  The 
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lower Hb group experienced a slightly lower rate of cardiovascular events, but it was 
nonsignificant (47 vs. 58 events, HR 0.78, 95% CI 0.53-1.14, P=0.20). The authors concluded, “In 
patients with chronic kidney disease, early complete correction of anemia does not reduce the 
risk of cardiovascular events.” 
 
A metanalysis of 9 trials and 5143 patients including data from CHOIR and CREATE was 
published in the Lancet in 2007. (34) Phrommintikul et al. identified a higher risk of overall 
mortality in patients treated to higher Hb targets (risk ratio 1.17, 95% CI 1.01–1.35; p=0.031). In 
the same analysis, a higher risk of access thrombosis was seen (1.34, 95% CI 1.16–1.54; 
p=0.0001) in patients treated to higher target Hb.  
 
Subsequent to the publication of these studies, the FDA placed a new black box warning on the 
epoetin alfa prescribing information in 2007. (35) The warning highlighted the increased risk of 
death and serious cardiovascular events when epoetin alfa was administered to a Hb greater 
than 12/g/dL. (36)  The prescribing information also deleted all QoL claims of epoetin 
treatment.  Shortly thereafter, the KDOQI guidelines were amended to reflect a revised target 
Hb range of 11-12 g/dL. (37)  
 
The largest and most recent RCT, the double-blinded, placebo-controlled Trial to Reduce 
Cardiovascular Events with Aranesp Therapy (TREAT), was published in 2009. (38) Pfeffer et al. 
studied 4038 patients with diabetes, nondialysis CKD (eGFR 20-60) and anemia. A total of 2012 
patients were randomized to darbepoetin to a target Hb of >13 while the comparison placebo 
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arm of 2026 patients was only treated with “rescue” darbepoetin if Hb fell to <9 g/dL. There 
was a nonsignificant trend toward an increased rate of the primary endpoint (composite of 
death, nonfatal MI, congestive heart failure, stroke or hospitalization for myocardial ischemia) 
among subjects in the higher target Hb group (632 vs. 630 events, HR 1.05, 95% CI 0.93-1.17, 
P=0.41). Attention was focused on a higher rate of stroke observed in the high target Hb group 
(101 vs. 53 events, HR 1.92, 95% CI 1.38-2.68, P <0.001).  
 
Response to Accumulated Evidence 
In early 2010, representatives from the FDA expressed concerns in an editorial about adverse 
events occurring in the course of therapy with ESAs. (39) Several potential hypotheses for the 
mechanism of harm were expressed. First, the notion that high Hb levels directly increase 
cardiovascular risk is possible. Arguing against this are suggestions from multiple studies in 
which high Hb levels were associated with less cardiovascular risk; though this itself may be 
confounded by healthier patients having higher Hb levels. Next, a particular concern to the FDA 
was the possibility that rapid changes in Hb, oscillations in level, and overshoots may be playing 
a role, supported by some internal FDA analyses. Due to these concerns, a more conservative 
dose escalation regimen was implemented in TREAT. Despite this conservative dose escalation, 
a higher risk of stroke was nonetheless observed in the high target Hb arm. Third, off target 
trophic effects on vascular cells and tumor growth could account for some of the risk. The 
editorial also observed that “the overall quality-of-life effects [in NHCT, CHOIR, and TREAT] 
were small and inconsistent.” 
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Systematic reviews and meta-analyses published in 2010 sought to clarify the evidence to date 
coinciding with the recent publication of TREAT. QoL was examined in paired reviews published 
in AJKD. Johansen and colleagues reviewed the evidence in CKD patients on dialysis. (40) 
Analysis was complicated because many studies reviewed lacked controls and a variety of 
different instruments were used to assess certain physical domains affecting QoL. The review 
found some reasonable evidence to support the notion that treatment with ESAs compared to 
placebo enhanced both VO2PEAK and physical functioning. However, they did not identify a 
conclusive benefit in treating moderate anemia (Hgb 10-12 g/dL) to levels above 12 g/dL.  
 
Gandra et al. performed a systematic analysis of QoL in nondialysis CKD patients. (41) Eight of 
eleven studies reported a statistically significant improvement in energy.  Gandra et al. also 
reported that 10 of 14 studies reported statistically significant improvements in physical 
function. Ultimately, these authors found a modest benefit to treating patients with untreated 
anemia (Hb <10 g/dL). However, the benefit of treating to higher targets (>13 g/dL) in terms of 
QoL could not be established.  
 
The accompanying editorial to both reviews noted the deficit of appropriately blinded placebo 
controlled RCTs in the literature on QoL. (42) The lack of placebo predisposes to potential bias 
from the benefit of being in a study. The lack of blinding could prejudice patients to an 
expectation of benefit. Overall, there was little evidence to support a Hb target of higher than 
12 g/dL. The available data lacked granularity to compare QoL with Hb increase from 10-11 g/dL 
to 11-12 g/dL, for example. 
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With respect to hard endpoints, a metanalysis published in May 2010 in Annals of Internal 
Medicine added TREAT data to pre-existing literature. (43) Utilizing data from 27 trials and 
10,452 patients, Palmer and colleagues found that higher vs. lower Hb treatment targets 
resulted in higher risk of stroke (relative risk [RR] 1.51; 95% CI 1.03-2.21), vascular access 
thrombosis (RR 1.33; 95% CI 1.16-1.53)) and hypertension (RR 1.67; 95% CI 1.31 to 2.12)). In 
contrast to the earlier metanalysis by Phrommintikul et al., with TREAT data included there was 
a nonsignificant trend toward increased mortality with higher Hb target (RR 1.09, 95% CI 0.99-
1.20). Similarly, there were nonsignificant trends toward increased cardiovascular end-points 
(RR 1.15, 95% CI 0.98-1.33) and progression to ESRD (RR 1.08, 95% CI 0.97-1.20)). The authors 
also reviewed the trials for QoL outcomes and noted that this evidence was of low quality 
overall, and at high risk for bias due to selective reporting of outcomes.  
 
The FDA modified dosing recommendations for ESAs again in June 2011, cautioning against 
raising Hb above 11 g/dL based on the risks noted in TREAT and earlier trials. (44) The new 
labels advised to “individualize dosing and use the lowest dose of ESA sufficient to reduce the 
need for red blood cell transfusions.” Later that year, the United States Center for Medicare 
Services, the largest payor for dialysis services in the country, changed payment rules by 
removing a Quality Incentive Program penalty for hemoglobin <10 g/dL, while maintaining the 
penalty for Hb >12 g/dL. (45) 
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Clinicians in the United States responded to these changing guidelines and payment incentives. 
ESA doses decreased in the US by approximately 30% between mid-year 2011 and 2013 in a 
sample of dialysis units. Average Hb levels decreased from approximately 11.2  
g/dL to 10.6 g/dL in the same period. (45) 
 
Recent Guidelines  
Kidney Disease Outcomes Quality Initiative (KDIGO) published guidelines for anemia in 2012. In 
these guidelines, it was recommended that ESA be administered to keep the Hb greater than 9 
g/dL and not to exceed 11.5 g/dL in most patients.  Individualization to higher Hb levels based 
on subjective quality of life was permitted, though an absolute ceiling of 13 g/dL was 
emphasized. (33) 
 
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) regularly 
updates guidelines for management of conditions including anemia of chronic kidney disease. 
The target Hb range has been 10-12 g/dL since 2011. Prior to that, no upper limit for Hb was 
recommended. In the most recent update in 2015, a footnote was added to emphasize the 
concern that treating to Hb levels more than 12 g/dL was associated with increased risk of 
mortality and cardiovascular morbidity in patients with CKD. (46) Trends in Hb targets as 
recommended by various agencies and organizations and changes over time are summarized in 
Figure 1.  
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Given the importance of patient-centered care in modern practice, some patients may express 
preferences that do not necessarily conform to the recommendations based on the best 
available evidence. Some authors have attempted to quantify the potential strength of patient 
desire to decrease transfusions or potentially improve fatigue vs. considerations such as risk of 
heart attack or stroke. Hauber et al. surveyed 200 patients coming to the National Kidney 
Foundation website for patient information. (47) They found patients would be willing to pay 
approximately $94 per month to decrease anemia symptoms by 25% to by 75%. The same 
patients would pay $118 to decrease blood transfusion from 2 per month to 0 (including travel 
and time spent in hospital getting infusion). However, they would also pay $119 per month to 
decrease the risk of dying from a heart attack or stroke from 6% to 0%. While these are 
important questions for certain patients, the validity and generalizability of these findings is 
uncertain.  
 
HIF-Stabilizers 
 
The risk vs. benefit proposition of higher target Hb levels has been based on ESA therapy, which 
is associated with high blood levels of the drug and may have off-target effects detrimental to 
cardiovascular tissues.  Hypoxia inducible factor (HIF) stabilizers, a new class of drugs to treat 
anemia in patients with CKD and ESRD, induce a low continuous level of endogenous 
erythropoietin (EPO) production in the kidney and liver and, by also inhibiting hepcidin and 
improving iron mobilization, are effective in raising Hb levels comparable to those achieved by 
ESAs.(48)  Whether HIF stabilizers are associated with fewer major adverse cardiovascular 
events (MACE) than ESAs at comparable target Hb levels has yet to be demonstrated and phase 
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3 trials of HIF stabilizers are currently underway with target Hb levels in the 10-12 g/dL range.  
It is possible that off-target effects of the HIF stabilizers may occur since these agents also 
induce the production of non-EPO proteins.  Should HIF stabilizers demonstrate less risk than 
ESAs at comparable target Hb levels, it is likely that studies will be performed to assess the 
MACE risk vs. QoL benefit ratio at higher target Hb levels.  A favorable result would reopen the 
discussion of the optimal Hb level in ESRD. 
 
Conclusion 
Through the past 3 decades we have witnessed an evolution in thinking about ESAs. Initially in 
1989 they were lauded as a panacea for renal anemia. The unexpected negative results of trials 
treating to normal Hb levels led to their classification as dangerous drugs with a progressively 
restrictive black box warning culminating in 2011.  The first iterations of the FDA label 
acknowledged a QoL benefit from ESAs because they were based on early studies in patients 
whose Hb levels increased from the 7-8 g/dL range without treatment to the 10-11 g/dL range 
with treatment.  Those were not placebo-controlled studies (as denying treatment to patients 
in the placebo arm was thought to be unethical) and QoL claims have subsequently been 
disallowed by the FDA if they are not based on active vs inactive treatment comparisons.  All 
the later RCTs compared ESA treatment to Hb levels in the 9 to 11.3 g/dL range to Hb levels in 
the 13-14 g/dL range.  Even TREAT had an ESA rescue for Hb levels less than 9 g/dL because it 
was thought to be unethical to allow Hb levels to go that low.  The QoL benefit of higher vs 
lower Hb targets was less demonstrable than treatment vs no treatment, so the FDA eliminated 
the QoL claims for ESAs and now acknowledges only a transfusion reduction benefit.  Similarly, 
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the FDA has taken the results of RCTs comparing target Hb levels of 9-11.3 vs 13-14 g/dL, and 
extrapolated the safety signal to increase at all target Hb levels and all ESA doses.  It should be 
noted that by not providing a target Hb level for ESA dosing (just the lowest dose to avoid 
transfusions), the FDA is alone among evidence-based practice guidelines on the subject 
including KDIGO, the European Renal Association (ERA) commentary on KDIGO and NICE, all of 
which recommend target Hb of 9-10 to 11.5-12 g/dL. (23, 46, 49)  Only the KDOQI commentary 
on the KDIGO guideline recommends a lower Hb target of 10-11 g/dL to be consistent with the 
FDA ESA label for dialysis patients. (50) However, the FDA ESA label for non-dialysis CKD 
patients recommends initiating ESA therapy when the Hb level is <10 then interrupting or 
discontinuing treatment when the Hb level is >10. (51) That is neither realistic or consistent 
with any other guideline on anemia treatment in patients with CKD. Medicare payment policy is 
based on this FDA label, making it very difficult to provide ongoing ESA therapy for Medicare 
patients with non-dialysis CKD.    
These challenges aside, the available studies point to a target Hb of 10-11 or 10-12 g/dL as 
being the best compromise between efficacy and safety; KDIGO offers a target Hb of 9-11.5 
g/dL, while still allowing individualization of treatment goals. Unless studies are done 
comparing a Hb target range of 10-11 vs. 11-12 g/dL, it is unlikely that further refinement in 
target Hb based on ESA therapy will be achievable in the near future. However, future 
investigations of HIF stabilizers could provide new answers to this persistent conundrum. 
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Table 1: Major Randomized Controlled Trials of ESAs Targeting Higher and Lower Hemoglobin Levels  
Study, Year Besarab et al. 
1998 
Furuland et al.  
2003 
Parfrey et al. 
2005 
Rossert et al. 
2006 
Drüeke et al. 
2006 
Singh et al. 
2006 
Pfeffer et al. 
2009 
Population/ 
inclusion  
criteria 
1233 HD1 
patients with 
heart failure or 
Ischemic Heart 
Disease  
416 CKD (HD, PD2 
& predialysis 
[creatinine >300 
mmol/L]) 
patients  
596 incident HD 
patients without 
symptomatic 
cardiac disease 
390 
predialysis 
patients 
(eGFR3 25-60 
ml/min) 
603 predialysis 
patients (eGFR 
15-35 
ml/min/1.73m2) 
with Hgb4 11-
12.5 g/dL 
1432 
predialysis  
patients (eGFR 
15-50 
ml/min/1.73 
m2) 
4036 diabetic 
predialysis 
patients (eGFR 
20-60 
ml/min/1.73m2) 
ESA Epoetin alfa Epoetin alfa Epoetin alfa Epoetin alfa Epoetin beta Epoetin alfa Darbepoetin alfa 
Blinding Double blind Open label Double blind Open label Open label Open label Double blind 
Hgb target (g/dL) 13-15 vs. 9-11 13.5-15 (women) 
14.5-16  (men)  
13.5-14.5  13-15 13-15  13.5 13.0 
Comparator Hgb (g/dL) 9-11  9-12  9.5-11.5  11-12 10.5-11.5 11.3 >9.0 
Achieved Hgb5 12.6 vs. 10.3 13.6 vs. 11.4 13.3 vs. 10.9 14.2 vs. 12 13.5 vs. 11.5 13.0 vs. 11.4 12.5 vs. 10.6 
Follow up time 
(months) 
29 (mean)  12-18 (50% 
completed) 
22 (56% 
completed) 
11.4 (high 
Hgb) 12.3 (low 
Hgb) 
36 (79% 
completed) 
36 (median 16) Median 29.1 
months 
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Primary end point Time to death 
or nonfatal MI6 
QoL7 on KDQ8, 
serious adverse 
events 
Left ventricular 
volume index 
Rate of GFR9 
decrease 
Time to first 
CV10 event  
Time to death, 
MI, CHF11, or 
stroke 
Time to death, 
MI, CHF, stroke, 
angina 
HR or RR (95% CI) or p-
value of Primary 
endpoint 
1.3 (0.9-1.9) 1.23 (P=0.32) for 
SAE’s12 
P=0.87 for 
difference 
P=0.976 for 
difference 
0.78 (0.53-1.14) 1.34 (1.03-
1.74) 
1.05 (0.94-1.17) 
 
Comment Study stopped 
early due to 
safety signal 
High withdrawal 
rate 
Relatively 
healthy HD 
population 
Stopped early 
due to 2 pts 
with PRCA13 
Lower event 
rate than 
anticipated 
Stopped early 
due to low 
probability of 
positive result 
Excess stroke in 
high Hgb arm 
Mortality (all-cause) 1.21 (1.01-1.46) 0.84 (0.50-1.40) 0.66 (0.33-1.30) 0.17 (0.02-
1.37) 
1.48 (0.87-2.52) 1.45 (0.96-
2.19) 
1.05 (0.92-1.21) 
Cardiovascular events NR14  NR NR 1.37 (0.93-
2.02) 
1.24 (0.87-1.76) 1.06 (0.96-
1.16) 
1.06 (0.96-1.16) 
Access thrombosis 
HR/RR (95% CI) 
1.37 (1.17-1.61) 2.16 (0.57-8.24) 1.19 (0.83-1.72) NR 1.31 (0.56-3.09) NR NR 
Stroke 1.55 (0.68-3.55) NR NR NR NR 1.00 (0.45-
2.22) 
1.92 (1.38-2.68) 
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Table 1 Footnotes: 1Hemodialysis; 2Peritoneal dialysis; 3estimated glomerular filtration rate; 4Hemoglobin; 5higher target achieved hemoglobin vs. lower target 
achieved hemoglobin; 6myocardial infarction; 7quality of life; 8Kidney Disease Questionnaire; 9glomerular filtration rate; 10cardiovascular; 11congestive heart 
failure; 12serious adverse events; 13pure red cell aplasia; 14not reported 
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Figure Legend: 
Figure 1. Key events in history of target hemoglobin in CKD. FDA, United States Food and Drug Administration; DOQI, Dialysis 
Outcomes Quality Initiative; CSN, Canadian Society of Nephrology; EBPG, European Best Practices Group; CARI, Caring for Australians 
with Renal Impairment; UK RA, United Kingdom Renal Association; KDOQI, Kidney Disease Outcomes Quality Initiative; UK NICE, 
United Kingdom National Institute for Health and Care Excellence. (4,5,9,10,13,16,27,29-33,35,38,44-46) 
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